Recursion Pharmaceuticals
RXRX
270 hedge funds and large institutions have $1.74B invested in Recursion Pharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 47 funds opening new positions, 111 increasing their positions, 53 reducing their positions, and 45 closing their positions.
109% more repeat investments, than reductions
Existing positions increased: 111 | Existing positions reduced: 53
88% more capital inflows, than outflows
Capital inflows: $190M | Capital outflows: $101M
4% more first-time investments, than exits
New positions opened: 47 | Existing positions closed: 45
0% more funds holding
Funds holding: 270 → 270 (0)
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
15.27% less ownership
Funds ownership: 109.46% → 94.19% (-15%)
42% less call options, than puts
Call options by funds: $11.4M | Put options by funds: $19.8M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ARK Investment Management
St. Petersburg,
Florida
|
+$33.2M |
| 2 |
State Street
Boston,
Massachusetts
|
+$29.5M |
| 3 |
BlackRock
New York
|
+$24.6M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$19.5M |
| 5 |
Deerfield Management
New York
|
+$16.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Laurion Capital Management
New York
|
-$21.8M |
| 2 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$9.7M |
| 3 |
Ghisallo Capital Management
Boston,
Massachusetts
|
-$8.25M |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$6.09M |
| 5 |
Perceptive Advisors
New York
|
-$5.77M |
RXRX Hedge Fund Activity: Q3 2024 in Review
270 of the 6,991 institutional investors tracked by Wall St. Rank reported a position in Recursion Pharmaceuticals (RXRX) for Q3 2024, worth a combined $1.74B — down 7.7% from $1.89B a quarter earlier.
Buyers outnumbered sellers: 47 funds opened new RXRX positions and 45 closed out — a net gain of 2 holders — while 111 added to existing stakes and 53 trimmed.
The largest buyer was ARK Investment Management, adding an estimated $33.2M. The largest seller was Laurion Capital Management, exiting entirely with an estimated $21.8M sold.
- 270 institutional investors held Recursion Pharmaceuticals (RXRX) as of Q3 2024, unchanged from Q2 2024.
- Funds reported $1.74B of Recursion Pharmaceuticals stock for Q3 2024, down 7.7% quarter-over-quarter.
- 47 funds opened new Recursion Pharmaceuticals positions in Q3 2024 and 45 closed out, a net change of +2 holders.
- The largest Recursion Pharmaceuticals buyer in Q3 2024 was ARK Investment Management, an estimated $33.2M added.
- The largest Recursion Pharmaceuticals seller in Q3 2024 was Laurion Capital Management, an estimated $21.8M sold.
Based on aggregated 13F filings for Q3 2024.